SCHEMBL12508705

SCHEMBL12508705

CC(=O)N/N=C/c1cc(OCCc2ccccc2)ccc1B(O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
CYP2D6 P10635 1/20 0.48
MAPK1 P28482 1/20 0.48
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 2/20 0.45
GAA P10253 2/20 0.45
PTGES O14684 1/20 0.44
ALOX5 P09917 1/20 0.44
PPARG P37231 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 1/20 0.44
MTNR1A P48039 2/20 0.43
MTNR1B P49286 2/20 0.43
POLB P06746 2/20 0.43
ADORA2A P29274 1/20 0.42
FFAR1 O14842 2/20 0.41
ALPL P05186 1/20 0.41
ALPI P09923 1/20 0.41
ALPG P10696 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12508296 0.83 ALDH1A1 (0.42) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL1129280 0.81 PTGES (0.50) MEN1KMT2APTGESALOX5PPARG
SCHEMBL12509033 0.78 CYP1A2 (0.55) MEN1KMT2AKDM4EALDH1A1RAB9A
SCHEMBL12419805 0.78 ALOX5 (0.48) PTGESALOX5PPARGFFAR1
SCHEMBL12508918 0.77 CYP1A2 (0.50) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL12419820 0.75 PPARG (0.47) KDM4EALDH1A1PTGESALOX5PPARG
SCHEMBL12419958 0.75 PTGES (0.49) MEN1KMT2APTGESALOX5PPARG
SCHEMBL12419963 0.75 PTGES (0.47) PTGESALOX5PPARGNPC1RAB9A
SCHEMBL12509035 0.72 LMNA (0.68) MEN1KMT2AMAPK1KDM4EALDH1A1
SCHEMBL17089342 0.72 RAB9A (0.50) MEN1KMT2ANPC1RAB9AFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 MEN1 4220/4885KMT2A 2097/4885CYP2D6 187/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 MEN1 4220/4885KMT2A 2097/4885CYP2D6 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.